"Efficacy Results from the Phase 2b SYNERGY Study: Treatment of Disabling Multiple Sclerosis with the Anti-LINGO-1 Monoclonal Antibody Opicinumab (S33.004)." Neurology
88.16 Supplement
(2017):
S33.004.
Web. 22 Mar. 2023.
Advertisement